Kayne Anderson Rudnick Investment Management LLC boosted its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 8.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,320 shares of the medical instruments supplier’s stock after purchasing an additional 6,131 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC owned 2.02% of Mesa Laboratories worth $11,396,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of MLAB. Pembroke Management LTD bought a new position in Mesa Laboratories in the 2nd quarter valued at about $8,283,000. Thomson Horstmann & Bryant Inc. increased its holdings in Mesa Laboratories by 75.4% in the 2nd quarter. Thomson Horstmann & Bryant Inc. now owns 72,362 shares of the medical instruments supplier’s stock valued at $10,370,000 after buying an additional 31,107 shares during the period. Royce & Associates LP increased its holdings in Mesa Laboratories by 56.8% in the 2nd quarter. Royce & Associates LP now owns 78,530 shares of the medical instruments supplier’s stock valued at $11,254,000 after buying an additional 28,458 shares during the period. Conestoga Capital Advisors LLC increased its holdings in Mesa Laboratories by 5.8% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 373,227 shares of the medical instruments supplier’s stock valued at $55,730,000 after buying an additional 20,489 shares during the period. Finally, Victory Capital Management Inc. increased its holdings in Mesa Laboratories by 11.8% in the 3rd quarter. Victory Capital Management Inc. now owns 147,468 shares of the medical instruments supplier’s stock valued at $22,020,000 after buying an additional 15,580 shares during the period. Institutional investors and hedge funds own 68.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/18/kayne-anderson-rudnick-investment-management-llc-has-11-40-million-holdings-in-mesa-laboratories-inc-mlab.html.

In other Mesa Laboratories news, Director H Stuart Campbell sold 1,000 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $130.16, for a total value of $130,160.00. Following the transaction, the director now directly owns 42,366 shares of the company’s stock, valued at approximately $5,514,358.56. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 15.70% of the stock is owned by company insiders.

Mesa Laboratories, Inc. (NASDAQ:MLAB) traded up $1.01 during mid-day trading on Friday, reaching $133.40. 28,217 shares of the company’s stock traded hands, compared to its average volume of 15,815. The company has a current ratio of 2.86, a quick ratio of 1.97 and a debt-to-equity ratio of 0.48. Mesa Laboratories, Inc. has a 52-week low of $113.57 and a 52-week high of $169.80. The company has a market cap of $500.40, a price-to-earnings ratio of 34.45 and a beta of 0.49.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing the consensus estimate of $0.64 by ($0.04). Mesa Laboratories had a net margin of 11.48% and a return on equity of 14.77%. The firm had revenue of $22.95 million during the quarter, compared to the consensus estimate of $25.50 million. equities research analysts forecast that Mesa Laboratories, Inc. will post 2.47 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Thursday, November 30th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.48%. The ex-dividend date of this dividend is Wednesday, November 29th. Mesa Laboratories’s dividend payout ratio is currently 23.10%.

Several research firms have commented on MLAB. Zacks Investment Research raised shares of Mesa Laboratories from a “strong sell” rating to a “buy” rating and set a $167.00 target price on the stock in a report on Tuesday, October 3rd. TheStreet lowered shares of Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st. Finally, BidaskClub lowered shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 31st.

Mesa Laboratories Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.